Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

The neuropathology of genetic Parkinson's disease.

Poulopoulos M, Levy OA, Alcalay RN.

Mov Disord. 2012 Jun;27(7):831-42. doi: 10.1002/mds.24962. Epub 2012 Mar 26. Review.

2.

Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations.

Alcalay RN, Levy OA, Waters CC, Fahn S, Ford B, Kuo SH, Mazzoni P, Pauciulo MW, Nichols WC, Gan-Or Z, Rouleau GA, Chung WK, Wolf P, Oliva P, Keutzer J, Marder K, Zhang X.

Brain. 2015 Sep;138(Pt 9):2648-58. doi: 10.1093/brain/awv179. Epub 2015 Jun 27.

3.

Analysis of LRRK2, SNCA, Parkin, PINK1, and DJ-1 in Zambian patients with Parkinson's disease.

Yonova-Doing E, Atadzhanov M, Quadri M, Kelly P, Shawa N, Musonda ST, Simons EJ, Breedveld GJ, Oostra BA, Bonifati V.

Parkinsonism Relat Disord. 2012 Jun;18(5):567-71. doi: 10.1016/j.parkreldis.2012.02.018. Epub 2012 Mar 24.

PMID:
22445250
4.

[Pathology of familial Parkinson's disease].

Wakabayashi K, Takahashi H.

Brain Nerve. 2007 Aug;59(8):851-64. Review. Japanese.

PMID:
17713121
5.

Clinical and pathological characteristics of LRRK2 G2019S patients with PD.

Poulopoulos M, Cortes E, Vonsattel JP, Fahn S, Waters C, Cote LJ, Moskowitz C, Honig LS, Clark LN, Marder KS, Alcalay RN.

J Mol Neurosci. 2012 May;47(1):139-43. doi: 10.1007/s12031-011-9696-y. Epub 2011 Dec 23.

6.

Substantia nigra hyperechogenicity with LRRK2 G2019S mutations.

Brüggemann N, Hagenah J, Stanley K, Klein C, Wang C, Raymond D, Ozelius L, Bressman S, Saunders-Pullman R.

Mov Disord. 2011 Apr;26(5):885-8. doi: 10.1002/mds.23644. Epub 2011 Feb 10.

7.

Fall risk and gait in Parkinson's disease: the role of the LRRK2 G2019S mutation.

Mirelman A, Heman T, Yasinovsky K, Thaler A, Gurevich T, Marder K, Bressman S, Bar-Shira A, Orr-Urtreger A, Giladi N, Hausdorff JM; LRRK2 Ashkenazi Jewish Consortium.

Mov Disord. 2013 Oct;28(12):1683-90. doi: 10.1002/mds.25587. Epub 2013 Oct 7.

PMID:
24123150
8.

Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.

Tsika E, Nguyen AP, Dusonchet J, Colin P, Schneider BL, Moore DJ.

Neurobiol Dis. 2015 May;77:49-61. doi: 10.1016/j.nbd.2015.02.019. Epub 2015 Feb 28.

PMID:
25731749
9.

Monogenic Parkinson's disease and parkinsonism: clinical phenotypes and frequencies of known mutations.

Puschmann A.

Parkinsonism Relat Disord. 2013 Apr;19(4):407-15. doi: 10.1016/j.parkreldis.2013.01.020. Epub 2013 Feb 23. Review.

PMID:
23462481
10.

Olfactory deficits and cardiac 123I-MIBG in Parkinson's disease related to the LRRK2 R1441G and G2019S mutations.

Ruiz-Martínez J, Gorostidi A, Goyenechea E, Alzualde A, Poza JJ, Rodríguez F, Bergareche A, Moreno F, López de Munain A, Martí Massó JF.

Mov Disord. 2011 Sep;26(11):2026-31. doi: 10.1002/mds.23773. Epub 2011 May 24.

PMID:
21611983
11.

Screening for the LRRK2 G2019S and codon-1441 mutations in a pathological series of parkinsonian syndromes and frontotemporal lobar degeneration.

Gaig C, Ezquerra M, Martí MJ, Valldeoriola F, Muñoz E, Lladó A, Rey MJ, Cardozo A, Molinuevo JL, Tolosa E.

J Neurol Sci. 2008 Jul 15;270(1-2):94-8. doi: 10.1016/j.jns.2008.02.010. Epub 2008 Mar 19.

PMID:
18353371
12.

[Clinical molecular genetics for PARK8 (LRRK2)].

Tomiyama H, Hatano T, Hattori N.

Brain Nerve. 2007 Aug;59(8):839-50. Review. Japanese.

PMID:
17713120
13.

Advances in GBA-associated Parkinson's disease--Pathology, presentation and therapies.

Barkhuizen M, Anderson DG, Grobler AF.

Neurochem Int. 2016 Feb;93:6-25. doi: 10.1016/j.neuint.2015.12.004. Epub 2015 Dec 30. Review.

PMID:
26743617
14.

Dyskinesias in patients with Parkinson's disease: effect of the leucine-rich repeat kinase 2 (LRRK2) G2019S mutation.

Yahalom G, Kaplan N, Vituri A, Cohen OS, Inzelberg R, Kozlova E, Korczyn AD, Rosset S, Friedman E, Hassin-Baer S.

Parkinsonism Relat Disord. 2012 Nov;18(9):1039-41. doi: 10.1016/j.parkreldis.2012.05.014. Epub 2012 Jun 13.

PMID:
22703868
15.

Motor phenotype of LRRK2-associated Parkinson's disease: a Tunisian longitudinal study.

Nabli F, Ben Sassi S, Amouri R, Duda JE, Farrer MJ, Hentati F.

Mov Disord. 2015 Feb;30(2):253-8. doi: 10.1002/mds.26097. Epub 2014 Dec 9.

PMID:
25487881
16.

The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease: is there a gender effect?

Orr-Urtreger A, Shifrin C, Rozovski U, Rosner S, Bercovich D, Gurevich T, Yagev-More H, Bar-Shira A, Giladi N.

Neurology. 2007 Oct 16;69(16):1595-602.

PMID:
17938369
17.

Biochemical and pathological characterization of Lrrk2.

Giasson BI, Covy JP, Bonini NM, Hurtig HI, Farrer MJ, Trojanowski JQ, Van Deerlin VM.

Ann Neurol. 2006 Feb;59(2):315-22.

PMID:
16437584
18.

What genetics tells us about the causes and mechanisms of Parkinson's disease.

Corti O, Lesage S, Brice A.

Physiol Rev. 2011 Oct;91(4):1161-218. doi: 10.1152/physrev.00022.2010. Review.

19.

Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease.

Lo Bianco C, Schneider BL, Bauer M, Sajadi A, Brice A, Iwatsubo T, Aebischer P.

Proc Natl Acad Sci U S A. 2004 Dec 14;101(50):17510-5. Epub 2004 Dec 2.

20.

G2019S LRRK2 mutation causing Parkinson's disease without Lewy bodies.

Gaig C, Martí MJ, Ezquerra M, Rey MJ, Cardozo A, Tolosa E.

J Neurol Neurosurg Psychiatry. 2007 Jun;78(6):626-8. Epub 2007 Jan 8.

Supplemental Content

Support Center